ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) (BEGIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00539838
Recruitment Status : Terminated (The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.)
First Posted : October 5, 2007
Last Update Posted : May 15, 2017
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Genentech, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : July 2011
  Actual Study Completion Date : September 2011
  Certification/Extension First Submitted : January 17, 2013